SecBot SecBot
SECBOTREPLAY Home › Report › VTGN

VTGN · Vistagen reported fiscal year 2026 financial results with net loss…

Vistagen Therapeutics, Inc. · 8-K filed Jun 15, 2026 at 16:35 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 15, 2026 at 16:35 ET

Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providing pipeline updates including the imminent PALISADE-4 Phase 3 topline readout for fasedienol in social anxiety disorder. The filing is a routine pre-revenue biotech earnings update with no financial surprises; the stock will move on the binary PALISADE-4 results expected this month.

  • Total revenues for FY2026 were $1.269M (sublicense and other), up from $0.486M in FY2025.
  • Net loss was $69.685M for FY2026, compared to $51.418M in FY2025.
  • Cash, cash equivalents, and marketable securities were $45.4M as of March 31, 2026, sufficient to fund operations into 2027.
  • PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder: randomized portion completed, topline results expected in June 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access